Rivastigmine

SKU: orb1310812

Description

Rivastigmine

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 123441-03-2
• MW: 250.34
• Purity: 99.32% (May vary between batches)
• Formula: C₁₄H₂₂N₂O₂
• SMILES: CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C
• Target: Cholinesterase (ChE)
• Solubility: DMSO:70 mg/mL (279.62 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.99 mM)

Bioactivity

• Target IC50:
  ChE:5.5 μM
• In Vivo:
  Preclinical biochemical studies indicates that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorates memory impairment in rats with forebrain lesions. The drug is rapidly absorbed orally, with a bioavailability of 0.355 and low protein binding (40%). Its elimination halflife is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dosedependent effects on AChE inhibition.
  Read more...
• Cell Research:
  Chronic toxicity is assessed 7 days after continuous exposure of cells to donepezil or rivastigmine using cell viability and cell esterase activity and the estimated cell numbers as parameters for viability. Culture medium including the tested drugs is changed once after 4 days.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Rivastigmine, S-Rivastigmine, SDZ-ENA-713, SDZ-ENA 713, SDZ-ENA713, parasympathomimetic, Parkinson's, orally, inhibit, Inhibitor, Exelon, AChE, acetylcholinesteras, Alzheimer's, BBB, BChE, butyrylcholinesterase, ChE, Cholinesterase (ChE), cholinesterase, cholinergic, disease

Compound Identifiers

PubChem CID

77991